176 related articles for article (PubMed ID: 21430379)
1. Castration-resistant prostate cancer: targeted therapies.
Leo S; Accettura C; Lorusso V
Chemotherapy; 2011; 57(2):115-27. PubMed ID: 21430379
[TBL] [Abstract][Full Text] [Related]
2. New therapies for castration-resistant prostate cancer: efficacy and safety.
Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
[TBL] [Abstract][Full Text] [Related]
3. Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer.
Clarke NW
BJU Int; 2012 Oct; 110 Suppl 1():14-22. PubMed ID: 23046036
[TBL] [Abstract][Full Text] [Related]
4. Abiraterone acetate for castration resistant prostate cancer.
Shah S; Ryan C
Expert Opin Investig Drugs; 2010 Apr; 19(4):563-70. PubMed ID: 20225998
[TBL] [Abstract][Full Text] [Related]
5. Zibotentan for the treatment of castrate-resistant prostate cancer.
Shepard DR; Dreicer R
Expert Opin Investig Drugs; 2010 Jul; 19(7):899-908. PubMed ID: 20497097
[TBL] [Abstract][Full Text] [Related]
6. Update on castrate-resistant prostate cancer: 2010.
Lassi K; Dawson NA
Curr Opin Oncol; 2010 May; 22(3):263-7. PubMed ID: 20177381
[TBL] [Abstract][Full Text] [Related]
7. Novel treatments for castration-resistant prostate cancer.
Sternberg CN
Eur J Cancer; 2011 Sep; 47 Suppl 3():S195-9. PubMed ID: 21943975
[TBL] [Abstract][Full Text] [Related]
8. Continued targeting of androgen receptor signalling: a rational and efficacious therapeutic strategy in metastatic castration-resistant prostate cancer.
Bianchini D; de Bono JS
Eur J Cancer; 2011 Sep; 47 Suppl 3():S189-94. PubMed ID: 21943974
[No Abstract] [Full Text] [Related]
9. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
[TBL] [Abstract][Full Text] [Related]
10. Castration-refractory prostate cancer: New drugs in the pipeline.
Schrijvers D; Van Erps P; Cortvriend J
Adv Ther; 2010 May; 27(5):285-96. PubMed ID: 20532721
[TBL] [Abstract][Full Text] [Related]
11. Preliminary results of tranilast treatment for patients with advanced castration-resistant prostate cancer.
Izumi K; Mizokami A; Shima T; Narimoto K; Sugimoto K; Kobori Y; Maeda Y; Konaka H; Koh E; Namiki M
Anticancer Res; 2010 Jul; 30(7):3077-81. PubMed ID: 20683058
[TBL] [Abstract][Full Text] [Related]
12. New therapeutic strategies for castration-resistant prostate cancer.
Tanaka T; Nakatani T
Recent Pat Anticancer Drug Discov; 2011 Sep; 6(3):373-83. PubMed ID: 21612574
[TBL] [Abstract][Full Text] [Related]
13. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
14. Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival.
Bournakis E; Efstathiou E; Varkaris A; Wen S; Chrisofos M; Deliveliotis C; Alamanis C; Anastasiou I; Constantinides C; Bamias A; Dimopoulos MA
Anticancer Res; 2011 Apr; 31(4):1475-82. PubMed ID: 21508406
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy for advanced prostate cancer: Looking through new lenses.
Vogiatzi P; Cassone M; Claudio L; Claudio PP
Drug News Perspect; 2009 Dec; 22(10):593-601. PubMed ID: 20140279
[TBL] [Abstract][Full Text] [Related]
16. Novel targeted therapies for prostate cancer.
Macfarlane RJ; Chi KN
Urol Clin North Am; 2010 Feb; 37(1):105-19, Table of Contents. PubMed ID: 20152524
[TBL] [Abstract][Full Text] [Related]
17. Castration-resistant prostate cancer--hormone therapy redux.
Tolcher AW; Cooper J
J Clin Oncol; 2010 Mar; 28(9):1447-9. PubMed ID: 20159817
[No Abstract] [Full Text] [Related]
18. Pathways of chemotherapy resistance in castration-resistant prostate cancer.
Mahon KL; Henshall SM; Sutherland RL; Horvath LG
Endocr Relat Cancer; 2011 Aug; 18(4):R103-23. PubMed ID: 21565970
[TBL] [Abstract][Full Text] [Related]
19. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
[TBL] [Abstract][Full Text] [Related]
20. [Epoch making development of new drugs for prostate cancer].
Akaza H
Gan To Kagaku Ryoho; 2013 Jan; 40(1):30-4. PubMed ID: 23306917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
